Dual-targeted BRAF/MEK inhibition with dabrafenib and trametinib improves therapeutic efficacy in BRAF V600E mutated NSCLC patients, achieving ORR and mPFS of 64% and 14.6 months (19). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.